Ask AI
ProCE Banner Activity

HER2-Directed ADCs in Bladder Cancer: Strategies to Personalize Treatment Selection and Optimize Patient Outcomes

Slideset

These downloadable slides highlight safety and efficacy data from key clinical trials of HER2-directed antibody–drug conjugates currently used to manage bladder cancer to optimize patient outcomes.

Released: December 02, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This activity has been designed to meet the educational needs of urologists, oncologists, and other healthcare professionals who care for patients with bladder cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess HER2 alterations in patients with bladder cancer to guide individualized clinical decisions

  • Evaluate the latest efficacy and safety data for HER2-targeted ADCs in bladder cancer to inform personalized treatment plans and supportive care for treatment-related adverse events (TRAEs)

  • Formulate care strategies for HER2 expressing bladder cancer that are informed by available clinical evidence and expert recommendations